Oncternal Therapeutics, Inc. Common Stock
ONCT
ONCT was delisted on the 2nd of December, 2024.
43 hedge funds and large institutions have $2.48M invested in Oncternal Therapeutics, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 10 increasing their positions, 12 reducing their positions, and 16 closing their positions.
17% more call options, than puts
Call options by funds: $61K | Put options by funds: $52K
10% less funds holding
Funds holding: 48 → 43 (-5)
17% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 12
25% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 16
47% less capital invested
Capital invested by funds: $4.66M → $2.48M (-$2.18M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$418K |
| 2 |
AFM
Anson Funds Management
Dallas,
Texas
|
+$379K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$307K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$289K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$156K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$410K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$386K |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
-$322K |
| 4 |
Millennium Management
New York
|
-$273K |
| 5 |
VC
Vivo Capital
Palo Alto,
California
|
-$165K |
ONCT Hedge Fund Activity: Q4 2018 in Review
43 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in Oncternal Therapeutics, Inc. Common Stock (ONCT) for Q4 2018, worth a combined $2.48M — down 47% from $4.66M a quarter earlier.
Sellers outnumbered buyers: 16 funds closed out of ONCT and 12 opened new positions — a net loss of 4 holders — while 12 trimmed existing stakes and 10 added.
The largest buyer was State Street, adding an estimated $418K. The largest seller was Candriam SCA, exiting entirely with an estimated $410K sold.
- 43 institutional investors held Oncternal Therapeutics, Inc. Common Stock (ONCT) as of Q4 2018, down from 48 in Q3 2018.
- Funds reported $2.48M of Oncternal Therapeutics, Inc. Common Stock stock for Q4 2018, down 47% quarter-over-quarter.
- 12 funds opened new Oncternal Therapeutics, Inc. Common Stock positions in Q4 2018 and 16 closed out, a net change of -4 holders.
- The largest Oncternal Therapeutics, Inc. Common Stock buyer in Q4 2018 was State Street, an estimated $418K added.
- The largest Oncternal Therapeutics, Inc. Common Stock seller in Q4 2018 was Candriam SCA, an estimated $410K sold.
Based on aggregated 13F filings for Q4 2018.